EUR 187.45
(0.83%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 604 Million EUR | -30.25% |
2022 | 400 Million EUR | -65.13% |
2021 | 1.14 Billion EUR | 17.4% |
2020 | 977 Million EUR | -9.87% |
2019 | 1.08 Billion EUR | -2.52% |
2018 | 1.11 Billion EUR | 3.44% |
2017 | 1.07 Billion EUR | 35.05% |
2016 | 796 Million EUR | 37.95% |
2015 | 577 Million EUR | 51.84% |
2014 | 380 Million EUR | 24.18% |
2013 | 306 Million EUR | -21.34% |
2012 | 389 Million EUR | 13.08% |
2011 | 344 Million EUR | 68.63% |
2010 | 204 Million EUR | -75.63% |
2009 | 837 Million EUR | 640.71% |
2008 | 113 Million EUR | -67.15% |
2007 | 344 Million EUR | -39.75% |
2006 | 571 Million EUR | 56.87% |
2005 | 364 Million EUR | -24.8% |
2004 | 484.01 Million EUR | -0.52% |
2003 | 486.54 Million EUR | -3.16% |
2002 | 502.39 Million EUR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q2 | 323 Million EUR | 0.0% |
2023 Q2 | 479 Million EUR | 0.0% |
2023 FY | 279 Million EUR | -30.25% |
2023 Q4 | 176 Million EUR | 0.0% |
2022 FY | 400 Million EUR | -65.13% |
2022 Q2 | 546 Million EUR | 0.0% |
2022 Q4 | 118 Million EUR | 0.0% |
2021 Q2 | 689 Million EUR | 0.0% |
2021 FY | 1.14 Billion EUR | 17.4% |
2021 Q4 | 613 Million EUR | 0.0% |
2020 FY | 977 Million EUR | -9.87% |
2020 Q4 | 471 Million EUR | 0.0% |
2020 Q2 | 607 Million EUR | 0.0% |
2019 Q4 | 529 Million EUR | 0.0% |
2019 FY | 1.08 Billion EUR | -2.52% |
2019 Q2 | 555 Million EUR | 0.0% |
2018 Q2 | 657 Million EUR | 0.0% |
2018 FY | 1.11 Billion EUR | 3.44% |
2017 Q4 | 512 Million EUR | 0.0% |
2017 FY | 1.07 Billion EUR | 35.05% |
2017 Q2 | 563 Million EUR | 0.0% |
2016 FY | 796 Million EUR | 37.95% |
2016 Q2 | 432 Million EUR | 0.0% |
2015 FY | 577 Million EUR | 51.84% |
2015 Q4 | 257 Million EUR | 0.0% |
2015 Q2 | 320 Million EUR | 0.0% |
2014 Q4 | 182 Million EUR | 0.0% |
2014 FY | 380 Million EUR | 24.18% |
2014 Q2 | 198 Million EUR | 0.0% |
2013 Q4 | 136 Million EUR | 0.0% |
2013 Q2 | 170 Million EUR | 0.0% |
2013 FY | 306 Million EUR | -21.34% |
2012 Q3 | 101.75 Million EUR | 0.0% |
2012 FY | 389 Million EUR | 13.08% |
2012 Q4 | 113.5 Million EUR | 11.55% |
2012 Q2 | 101.75 Million EUR | 0.0% |
2012 Q1 | 101.75 Million EUR | 0.0% |
2011 Q1 | 112 Million EUR | 0.0% |
2011 Q2 | 112 Million EUR | 0.0% |
2011 Q3 | 112 Million EUR | 0.0% |
2011 Q4 | 101.75 Million EUR | -9.15% |
2011 FY | 344 Million EUR | 68.63% |
2010 Q4 | 112 Million EUR | 111.32% |
2010 Q2 | 53 Million EUR | 0.0% |
2010 Q3 | 53 Million EUR | 0.0% |
2010 Q1 | 53 Million EUR | 0.0% |
2010 FY | 204 Million EUR | -75.63% |
2009 Q4 | 53 Million EUR | -76.52% |
2009 FY | 837 Million EUR | 640.71% |
2009 Q2 | 225.75 Million EUR | 0.0% |
2009 Q3 | 225.75 Million EUR | 0.0% |
2009 Q1 | 225.75 Million EUR | 0.0% |
2008 Q3 | 49.25 Million EUR | 0.0% |
2008 FY | 113 Million EUR | -67.15% |
2008 Q1 | 49.25 Million EUR | 0.0% |
2008 Q2 | 49.25 Million EUR | 0.0% |
2008 Q4 | 225.75 Million EUR | 358.38% |
2007 Q4 | 49.25 Million EUR | -49.1% |
2007 FY | 344 Million EUR | -39.75% |
2007 Q3 | 96.75 Million EUR | 0.0% |
2007 Q2 | 96.75 Million EUR | 0.0% |
2007 Q1 | 96.75 Million EUR | 0.0% |
2006 Q3 | 146.5 Million EUR | 0.0% |
2006 Q4 | 96.75 Million EUR | -33.96% |
2006 Q2 | 146.5 Million EUR | 0.0% |
2006 FY | 571 Million EUR | 56.87% |
2006 Q1 | 146.5 Million EUR | 0.0% |
2005 Q4 | 146.5 Million EUR | -30.81% |
2005 FY | 364 Million EUR | -24.8% |
2005 Q2 | 211.75 Million EUR | 0.0% |
2005 Q3 | 211.75 Million EUR | 0.0% |
2005 Q1 | 211.75 Million EUR | 0.0% |
2004 Q2 | 123.12 Million EUR | 0.0% |
2004 FY | 484.01 Million EUR | -0.52% |
2004 Q1 | 123.12 Million EUR | 0.0% |
2004 Q3 | 123.12 Million EUR | 0.0% |
2004 Q4 | 211.75 Million EUR | 71.98% |
2003 Q4 | 123.12 Million EUR | 2.63% |
2003 Q3 | 119.97 Million EUR | 0.0% |
2003 Q1 | 119.97 Million EUR | 0.0% |
2003 Q2 | 119.97 Million EUR | 0.0% |
2003 FY | 486.54 Million EUR | -3.16% |
2002 Q3 | 123.05 Million EUR | 0.0% |
2002 Q2 | 123.05 Million EUR | 0.0% |
2002 Q1 | 123.05 Million EUR | 0.0% |
2002 FY | 502.39 Million EUR | 0.0% |
2002 Q4 | 119.97 Million EUR | -2.51% |
2001 Q4 | 123.05 Million EUR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
ABIONYX Pharma SA | -3.41 Million EUR | 17802.227% |
ABIVAX Société Anonyme | -127.37 Million EUR | 574.187% |
Adocia SA | -17.62 Million EUR | 3527.534% |
Aelis Farma SA | -6.46 Million EUR | 9448.398% |
Biophytis S.A. | -14.33 Million EUR | 4314.051% |
Advicenne S.A. | -6.45 Million EUR | 9454.189% |
genOway Société anonyme | 2.06 Million EUR | -29145.203% |
IntegraGen SA | -183.77 Thousand EUR | 328771.709% |
Medesis Pharma S.A. | -4.22 Million EUR | 14381.185% |
Neovacs S.A. | -6.9 Million EUR | 8844.057% |
NFL Biosciences SA | -4.43 Million EUR | 13733.019% |
Plant Advanced Technologies SA | -778.23 Thousand EUR | 77711.319% |
Quantum Genomics Société Anonyme | -3.13 Million EUR | 19352.506% |
Sensorion SA | -22.31 Million EUR | 2807.23% |
Theranexus Société Anonyme | -7.64 Million EUR | 8001.956% |
TME Pharma N.V. | -5.62 Million EUR | 10839.687% |
Valbiotis SA | -7.16 Million EUR | 8535.754% |
TheraVet SA | -2.17 Million EUR | 27868.723% |
Valerio Therapeutics Société anonyme | -20.28 Million EUR | 3077.129% |
argenx SE | -417.15 Million EUR | 244.791% |
BioSenic S.A. | -7.04 Million EUR | 8679.545% |
Celyad Oncology SA | -8.45 Million EUR | 7242.013% |
DBV Technologies S.A. | -85.24 Million EUR | 808.536% |
Galapagos NV | -88.26 Million EUR | 784.318% |
Genfit S.A. | -26.58 Million EUR | 2372.385% |
GeNeuro SA | -14.35 Million EUR | 4306.919% |
Hyloris Pharmaceuticals SA | -15.99 Million EUR | 3876.652% |
Innate Pharma S.A. | -12.66 Million EUR | 4867.543% |
Inventiva S.A. | -102.7 Million EUR | 688.069% |
MaaT Pharma SA | -19.94 Million EUR | 3128.632% |
MedinCell S.A. | -20.97 Million EUR | 2979.344% |
Nanobiotix S.A. | -26.77 Million EUR | 2355.499% |
Onward Medical N.V. | -35.46 Million EUR | 1803.184% |
Oryzon Genomics S.A. | -4.54 Million EUR | 13377.08% |
OSE Immunotherapeutics SA | -22.98 Million EUR | 2727.686% |
Oxurion NV | -12.11 Million EUR | 5087.614% |
Pharming Group N.V. | -4.87 Million EUR | 12478.206% |
Poxel S.A. | -28.76 Million EUR | 2199.847% |
GenSight Biologics S.A. | -29.69 Million EUR | 2133.944% |
Transgene SA | -30.01 Million EUR | 2112.528% |
Financière de Tubize SA | -2.14 Million EUR | 28271.983% |
Valneva SE | -82.08 Million EUR | 835.805% |
Vivoryon Therapeutics N.V. | -28.83 Million EUR | 2194.531% |